{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-012173","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.838180+00:00","generated_at":"2026-05-26T22:49:48.438526+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rezolute reports Q2 net loss $15.7M; ersodetug gets Breakthrough Therapy, Orphan Drug status","bullets":["Cash & equivalents $105.3M at Dec 31, 2024 vs $127.1M at June 30, 2024.","Net loss $15.7M for Q2 fiscal 2025 vs $13.9M for same period last year.","FDA granted Breakthrough Therapy Designation for ersodetug in congenital hyperinsulinism (HI).","FDA granted Orphan Drug Designation for ersodetug in tumor HI.","Phase 3 sunRIZE study interim analysis planned this quarter; topline results expected Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-012173","json":"https://secwatch.observer/filing/0001104659-25-012173.json","markdown":"https://secwatch.observer/filing/0001104659-25-012173.md","text":"https://secwatch.observer/filing/0001104659-25-012173.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465925012173/0001104659-25-012173-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465925012173/tm255593d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:49:48.438526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}